1,3-dihydro-1-hydroxy-2,1-Benzoxaborole-7-propanoic acid
1,3-dihydro-1-hydroxy-2,1-Benzoxaborole-7-propanoic acid Basic information
- Product Name:
- 1,3-dihydro-1-hydroxy-2,1-Benzoxaborole-7-propanoic acid
- Synonyms:
-
- 1,3-dihydro-1-hydroxy-2,1-Benzoxaborole-7-propanoic acid
- 3-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-7-yl)propanoic acid
- 3-(1-Hydroxy-1,3-dihydro-2,1-benzoxaborol-7-yl)propanoic acid
- AN3661
- AN3661,AN-3661
- 2,1-Benzoxaborole-7-propanoic acid, 1,3-dihydro-1-hydroxy-
- CAS:
- 1268335-33-6
- MF:
- C10H11BO4
- MW:
- 206
- Mol File:
- 1268335-33-6.mol
1,3-dihydro-1-hydroxy-2,1-Benzoxaborole-7-propanoic acid Chemical Properties
- Melting point:
- 150-151 °C
- Boiling point:
- 402.7±55.0 °C(Predicted)
- Density
- 1.31±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO: 250 mg/mL (1213.59 mM)
- pka
- 4.52±0.10(Predicted)
- form
- Solid
- color
- White to off-white
1,3-dihydro-1-hydroxy-2,1-Benzoxaborole-7-propanoic acid Usage And Synthesis
Biological Activity
AN3661, a potent antimalarial lead compound, targets Plasmodium falciparum cleavage and polyadenylate-specific factor homolog subunit 3 (PfCPSF3). It inhibits infection of laboratory-adapted strains of Plasmodium falciparum (mean IC50=32 nM), Ugandan field isolates (mean IC50=64 nM) and mice P. berghei and P. falciparum.
in vitro
AN3661 is active at nanomolar (IC 50 =20-56 nM) concentrations against P. falciparum laboratory strains known to be sensitive (3D7) or resistant (W2, Dd2, K1, HB3, FCR3 and TM90C2B), and AN3661 is similarly active in ex vivo studies of fresh Ugandan field isolates (mean ex vivo IC 50 =64 nM). AN3661 shows minimal cytotoxicity against mammalian cell lines, with the CC 50 60.5 μM against Jurkat cells, and all other CC 50 values greater than the highest concentrations tested (25 μM or above).
AN3661 inhibits the stability of P. falciparum transcripts.
in vivo
AN3661 (50-200 mg.kg; po; daily for 4 days) inhibits murine P. berghei infections with ED 90 (4 days) 0.34 mg/kg.
AN3661 is administered orally for 4 days, beginning on the third day of infection, the ED 90 4 days after initiation of treatment is 0.57 mg/kg.
| P. berghei -infected mice (malaria model) | |
| Dosage: | 50, 100, 200 mg/kg |
| Administration: | Orally; daily for 4 days |
| Result: | Rapidly controlled parasitemias, with an ED 90 of 0.34 mg/kg. Daily dosages of 50 mg/kg and 100 mg/kg extended survival, and mice treated with 200 mg/kg per day demonstrated long-term cures. |
1,3-dihydro-1-hydroxy-2,1-Benzoxaborole-7-propanoic acidSupplier
- Tel
- 010-60400365-8001 19906534436
- service@bellenchem.com
- Tel
- 571-89925085
- sales@amadischem.com
- Tel
- 010-60605840 18892239720
- psaitong@jm-bio.com
- Tel
- 400-9205774
- sales@glpbio.cn
- Tel
- 0512-65816829 18662214788
- info@rovathin.com.cn